Hido Technologies Inc
AI robotic device ensuring in-home medication adherence.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
Hido Technologies Inc., founded in 2018, is a digital health company that has developed an AI-powered robotic device to improve medication adherence for patients at home. The company was co-founded by CEO Charles Gellman and CTO Brandon Woolsey. Gellman's venture into health technology was spurred by a personal medical misdiagnosis, which exposed him to the challenges within the healthcare system and inspired him to find a solution for at-home patient care. Woolsey, a biomedical engineer, provided the technical expertise to bring Gellman's vision to life, starting the initial designs in a two-car garage.
Hido's core product is an internet-connected device that automates medication dispensing and uses video, voice analysis, and other sensors to monitor consumption. The system is designed to ensure the six rights of medication safety: right patient, drug, dose, route, time, and documentation. It employs features like FaceID for patient verification, RFID sensors on pill bottles, and passively records medication events, which are then reported to caregivers and providers. This reduces the burden on patients and caregivers, especially those dealing with chronic conditions like dementia and congestive heart failure. By creating a detailed log of medication intake, the technology provides data insights that were previously unavailable in a home setting, enabling what the company calls precision medicine.
The company operates on a B2B model, targeting clients such as Medicare Advantage payers, long-term care insurance providers, and academic medical centers. Its value proposition is centered on reducing healthcare costs by preventing unnecessary hospitalizations and emergency room visits that often result from medication non-adherence. Studies involving Hido's device have shown significant outcomes, including an 80% reduction in hospitalizations for congestive heart failure patients. The company has secured over $4.5 million in funding, including $1.5 million in seed funding and over $3 million in non-dilutive grants from institutions like the National Institutes of Health (NIH).
Keywords: medication adherence, remote patient monitoring, digital health, health technology, AI robotics, in-home care, chronic disease management, dementia care, congestive heart failure, medication dispensing, telehealth, value-based care, patient monitoring devices, healthcare data analytics, precision medicine, gerontechnology, assistive technology, home healthcare, medication management systems, remote therapy